{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.7","upperLimit":"71.9","value":"61.3"},{"groupId":"OG001","lowerLimit":"5.3","upperLimit":"85.3","value":"40.0"},{"groupId":"OG002","lowerLimit":"23.1","upperLimit":"56.5","value":"38.9"},{"groupId":"OG003","lowerLimit":"27.7","upperLimit":"57.9","value":"42.2"},{"groupId":"OG004","lowerLimit":"20.2","upperLimit":"59.4","value":"38.5"},{"groupId":"OG005","lowerLimit":"51.3","upperLimit":"66.0","value":"58.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"182"}],"units":"Participants"}],"description":"CyR is based on the prevalence of Ph+ cells. MCyR was categorized as either CCyR or PCyR. CCyR was achieved when there was 0% Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or \\<1% positive cells from at least 200 cells analyzed from FISH. PCyR was achieved when 1 to 35% Ph+ cells were present.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG001","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG005","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"}],"paramType":"NUMBER","populationDescription":"Cytogenetic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline cytogenetic assessment.","reportingStatus":"POSTED","timeFrame":"Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L) or Year 5 (CP2L)","title":"Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line and Chronic Phase Third-line CML Population - Part 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}